Gl. Phillips et al., PROPHYLAXIS FOR ACUTE GRAFT-VERSUS-HOST DISEASE FOLLOWING UNRELATED DONOR BONE-MARROW TRANSPLANTATION, Bone marrow transplantation, 15(2), 1995, pp. 213-219
Despite the use of conventional chemoprophylaxis regimens, patients re
ceiving unrelated-donor BMT are at high risk of developing severe acut
e GVHD. We evaluated a prophylactic regimen combining CsA, MTX and ant
i-CD5-ricin A chain immunotoxin (H65-RTA) in 31 patients; pentoxifylli
ne was also given to reduce the anticipated nephrotoxicity of CsA. In
most cases, planned doses of CsA, MTX and H65-RTA were given (i.e. to
77%, 77% and 93% of patients, respectively). Although fluid retention
requiring diuretic therapy was frequent, only 1 patient had a >10% une
xplained increase in body weight during the first 21 days post-BMT. Al
so, while significant increase of the baseline serum creatinine was no
ted in 7 patients, none required dialysis. One patient suffered a reve
rsible allergic reaction to the immunotoxin; no other side effects att
ributable to this regimen were observed. All but 2 patients engrafted
(1 died of fungemia on d + 19 and the other had persistent leukemia) a
nd no late graft failures were observed. Seventeen patients developed
acute GVHD grade greater than or equal to II (probability, 58% [95% CI
41-76%]); 7 had grade greater than or equal to III (probability, 24%
[95% CI 12-43%]). In the 27 patients who achieved stable engraftment a
nd have survived beyond d + 100, the 3-year probability of developing
chronic GVHD was 66% (95% CI 48-84%). As of the last follow-up prior t
o 01 May 1994, 13 patients are alive in CR and one in relapse; 9 of th
ese patients are off all immunosuppressives and well. Four other patie
nts relapsed and died, and 13 died of other transplant-related causes.
Event-free survival (EFS) is 46% (95% CI 27-63%) at 3 yrs, with a med
ian followup of 33 mos (range 19-42) in survivors. This regimen may di
minish the severity of acute GVHD without a high incidence of graft re
jection. The relatively low relapse rate observed to date suggests the
persistence of an allogeneic antitumor effect. These preliminary resu
lts require confirmation.